Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

NCT07225439 is registered in ClinicalTrials.gov with Paolo Caimi, MD as lead sponsor.

NCT NCT07225439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07225439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
Lead sponsor
Paolo Caimi, MD
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2026
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, non hodgkin lymphoma, primary mediastinal large b cell lymphoma, small lymphocytic lymphoma